Discover
INBX
Inhibrx Biosciences Inc.
86.00
1 x 85.86
1 x 89.57
bid
ask
-
1.61
1.84%
09:32 AM
timesize
| Ytd | 8.86% | |
| 1y | 276.20% |
87.48
day range
87.48
20.55
52 week range
155.29
| Open | 87.48 | Prev Close | 87.61 | Low | 87.48 | High | 87.48 | Mkt Cap | 1.29B |
| Vol | 1.84K | Avg Vol | 463.36K | EPS | -8.39 | P/E | -10.44 | Forward P/E | -14.76 |
| Beta | 3.41 | Short Ratio | 10.24 | Inst. Own | 82.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 98.66 | 200-d Avg | 81.86 | 1yr Est | 277.50 |
| Income Statement | |||
| Operating Expenses | 30.93M | ||
| Research and Development Expense | 25.22M | ||
| Selling, General and Administrative Expense | 5.71M | ||
| Operating Income | -30.93M | ||
| Interest Expense | 3.51M | ||
| Net Income | -33.44M | ||
| Net Income Common Stock | -33.44M | ||
| Net Income Common Stock (USD) | -33.44M | ||
| Consolidated Income | -33.44M | ||
| Earnings per Basic Share | -2.15 | ||
| Earnings per Basic Share (USD) | -2.15 | ||
| Earnings per Diluted Share | -2.15 | ||
| Earning Before Interest & Taxes (EBIT) | -29.93M | ||
| Earning Before Interest & Taxes (USD) | -29.93M | ||
| Weighted Average Shares | 15.59M | ||
| Weighted Average Shares Diluted | 15.59M | ||
| Balance Sheet | |||
| Cash and Equivalents | 161.66M | ||
| Cash and Equivalents (USD) | 161.66M | ||
| Trade and Non-Trade Receivables | 186.00K | ||
| Current Assets | 171.34M | ||
| Property, Plant & Equipment Net | 8.25M | ||
| Total Assets | 183.97M | ||
| Debt Current | 2.41M | ||
| Total Debt | 180.90M | ||
| Current Liabilities | 26.51M | ||
| Debt Non-Current | 178.49M | ||
| Total Liabilities | 205.00M | ||
| Accumulated Retained Earnings (Deficit) | -279.63M | ||
| Shareholders Equity | -21.03M | ||
| Shareholders Equity (USD) | -21.03M | ||
| Assets Non-Current | 12.63M | ||
| Total Debt (USD) | 180.90M | ||
| Liabilities Non-Current | 178.49M | ||
| Trade and Non-Trade Payables | 8.76M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.02M | ||
| Net Cash Flow from Financing | 75.46M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 37.44M | ||
| Issuance (Purchase) of Equity Shares | 471.00K | ||
| Issuance (Repayment) of Debt Securities | 74.99M | ||
| Net Cash Flow from Operations | -38.03M | ||
| Share Based Compensation | 2.65M | ||